Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Jul-Aug;66(4):459-61.
doi: 10.1016/j.ihj.2014.05.016. Epub 2014 Jun 10.

Bioresorbable vascular scaffold for coronary in-stent restenosis: a novel concept

Surender Deora  1 , Sanjay Shah  2 , Samir Pancholy  3 , Tejas Patel  2
Affiliations
Case Reports

Bioresorbable vascular scaffold for coronary in-stent restenosis: a novel concept

Surender Deora et al. Indian Heart J. 2014 Jul-Aug.

Abstract

The management of patients with significant in-stent restenosis (ISR) with drug-eluting stent is still not well defined. Various treatment modalities include plain old balloon angioplasty (POBA), metallic stent, cutting or scoring balloon and drug-eluting balloon (DEB). Bioresorbable vascular scaffold (BVS) is the latest technology for the treatment of de novo coronary artery lesions. The use of BVS in ISR is based on the rationale of local drug delivery as achieved by DEB without the permanent bi-layer of metal and also stabilizes dissection flaps and prevents acute recoil as provided by metallic stent. To the best of our knowledge this is the first case report of the use of BVS in patient with ISR.

Keywords: Bioresorbable vascular scaffold; Drug-eluting balloon; Drug-eluting stent; In-stent restenosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Left coronary angiogram in RAO caudal (Panel A) and AP cranial view showing significant ISR in proximal LAD (Arrow, Panel B). AP caudal view showing rotablation with 1.5 mm burr (Arrow, Panel C) and predilation with PTCA balloon dilatation catheter (Arrow, Panel D) (RAO, Right anterior oblique; AP, Anterio–posterior; ISR, In-stent restenosis; LAD, left anterior descending artery; PTCA, Percutaneous transluminal coronary angioplasty).
Fig. 2
Fig. 2
BVS platinum markers representing the edges of the scaffold are seen placed across the lesion in RAO caudal (Arrow, Panel A) and AP cranial view (Arrow, Panel B) confirming the proper position of the scaffold (BVS, Bioresorbable scaffold; RAO, Right anterior oblique; AP, Anterio–posterior).
See this image and copyright information in PMC

References

    1. Dangas G.D., Claessen B.E., Caixeta A., Sanidas E.A., Mintz G.S., Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897–1907. - PubMed
    1. Torguson R., Sabate M., Deible R. Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. Am J Cardiol. 2006;98:1340–1344. - PubMed
    1. Lemos P.A., van Mieghem C.A., Arampatzis C.A. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes. Circulation. 2004;109:2500–2502. - PubMed
    1. Chatani K., Muramatsu T., Tsukahara R. Predictive factors of re-restenosis after repeated sirolimus-eluting stent implantation for SES restenosis and clinical outcomes after percutaneous coronary intervention for SES restenosis. J Interv Cardiol. 2009;22:354–361. - PubMed
    1. Song H.G., Park D.W., Kim Y.H. Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation. J Am Coll Cardiol. 2012;59:1093–1100. - PubMed

LinkOut - more resources